Concomitantly discovered visceral artery aneurysms do rarely grow during cancer therapy

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Aaron Becker von Rose - , Klinikum Rechts der Isar (MRI TUM) (Author)
  • Kathrin Kobus - , Technical University of Munich (Author)
  • Bianca Bohmann - , Technical University of Munich (Author)
  • Matthias Trenner - , Technical University of Munich (Author)
  • Adam Wahida - , Klinikum Rechts der Isar (MRI TUM) (Author)
  • Hans-Henning Eckstein - , Technical University of Munich (Author)
  • Florian Bassermann - , Klinikum Rechts der Isar (MRI TUM) (Author)
  • Korbinian von Heckel - , Hospital of the Ludwig-Maximilians-University (LMU) Munich (Author)
  • Steffen Wolk - , Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus Dresden (Author)
  • Christian Reeps - , Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus Dresden (Author)
  • Benedikt J Schwaiger - , Technical University of Munich (Author)
  • Wolf-Hans Eilenberg - , Medical University of Vienna (Author)
  • Christoph Neumayer - , Medical University of Vienna (Author)
  • Christoph Burghuber - , Medical University of Vienna (Author)
  • Albert Busch - , Department of Visceral, Thoracic and Vascular Surgery, Klinikum Rechts der Isar (MRI TUM), University Hospital Carl Gustav Carus Dresden (Author)

Abstract

Visceral artery aneurysms (VAA) are a rare entity of arterial aneurysms with the imminent threat of rupture. The impact of cancer and chemotherapy on the growth of VAAs is unknown. A retrospective dual center cohort study of patients with concomitant VAA and different types of cancer was conducted and the impact of various chemotherapeutic agents on VAA growth was studied by sequential CT analysis. For comparison, a non-cancer all comer cohort with VAAs and no cancer was studied to compare different growth rates. The primary endpoint was aneurysm progress or regression >1.75 mm. Chi-square test, Fisher's exact test and Mann–Whitney test was used for statistical comparison. In the 17-year-period from January 2003 to March 2020, 59 patients with 30 splenic artery aneurysms, 14 celiac trunk aneurysms, 11 renal artery aneurysms and 4 other VAA and additional malignancy were identified. 20% of patients suffered from prostate cancer, the rest were heterogeneous. The most prevalent chemotherapies were alkylating agents (23%), antimetabolites (14%) and mitose inhibitors (10%). Eight patients had relevant growth of their VAA and one patient showed diameter regression (average growth rate 0.1 ± 0.5 mm/year). Twenty-nine patients with 14 splenic, 11 RAAs (seven right) and 4 celiac trunk aneurysms were available in the non-cancer comparison cohort (average growth rate 0.5 ± 0.9 mm/year, p = 0.058). However, the growth rate of patients receiving operative treatment for relevant VAA growth was significantly higher (p = 0.004). VAAs grow rarely, and rather slow. Cancer and/or chemotherapy do not significantly influence the annual growth rate. Additional control examinations seem unnecessary.

Details

Original languageEnglish
Pages (from-to)296-304
Number of pages9
JournalClinical Anatomy
Volume35
Issue number3
Publication statusPublished - Apr 2022
Peer-reviewedYes

External IDs

PubMed 34837270

Keywords

Sustainable Development Goals

ASJC Scopus subject areas

Keywords

  • aneurysm growth, chemotherapy, visceral artery aneurysm

Library keywords